Gufic BioSciences Ltd (GUFICBIO)
₹451.70
Mkt cap
₹4,462 Cr
P/E ratio
60.70
P/B
6.82
Div yield
0.02%
ROE
9.98%
ROCE
12.20%
EPS (TTM)
₹7.44
Book value
₹66
52W range
274–452
Sector
Healthcare
Price history
Previous close
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
NSE GUFICBIOBSE 509079
Health check
Constructive
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
0.00% from high₹452
₹274+65.16% from low₹452
Current
₹451.70
Prev close
₹446.00
Day
+1.28%
Price performance
1D
+1.28%
1W
+8.49%
1M
+7.19%
3M
+16.78%
6M
+65.16%
1Y
+24.40%
YTD
+34.04%
Financials
Revenue, profit & margin
P/E ratio
60.7×
GUFICBIO is 79% above the sector median of 34.0×
GUFICBIO60.7×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 | 231 | 252 | 261 | |
| Expenses | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 | 195 | 206 | 214 | |
| Operating Profit | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 | 36 | 46 | 47 | |
| OPM % | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% | 16% | 18% | 18% | |
| Other Income | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 | |
| Interest | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 | |
| Profit before tax | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 | 21 | 28 | 30 | |
| Tax % | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | |
| Net Profit | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 | 16 | 21 | 22 | |
| EPS in Rs | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 | 1.55 | 2.05 | 2.24 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.95% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | −0.95% |
| +1 day | −0.19% |
| +5 days | −0.99% |
| +15 days | — |
| +30 days | — |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.50%Promoter
Promoters72.50%
FIIs0.47%0.05
DIIs3.67%0.16
Public23.36%0.13
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| GUFICBIO | ₹444.90 | 60.68 | 4,462 | 0.02% | 22 | +86.08% | 261 | +14.94% | 12.17% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012nse
Concall transcripts51
TranscriptAug 2025TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Outcome of AGM 4 Sep - Gufic Biosciences held its 42nd AGM on September 4, 2026; approved 10% final dividend and director reappointments.Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Promotion And Change In Designation Of Senior Management Personnel 2 Sep - Ami Shah promoted to Head-Legal; Pinak Padhya promoted to President-Sales & Marketing from September 2, 2026.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 21 Aug - Written Transcript of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewithAnnouncement under Regulation 30 (LODR)-Newspaper Publication 18 Aug - Newspaper advertisement regarding Special Window for re-lodgement of transfer and dematerialization of physical shares is attached herewithAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 17 Aug - Audio recording of earnings conference call held on August 17, 2026 uploaded.